New Phase IV QMR Pricing Plan

Quorum Review has developed a new pricing plan for Phase IV clinical studies. Studies that meet the criteria below will qualify for the new pricing schedule. The schedule features very aggressive price breaks for initial review and continuing review of sites. There are further discounts based on volume of sites; one pricing structure for 50-100 sites, another for 100-300 sites, and a final structure for 300+ sites.

Studies must meet the following criteria to qualify.

  • The study qualifies for expedited review as “minimal risk” according to U.S. federal regulatory standards;
  • The protocol imposes a fixed compensation schedule on all investigators;
  • The sponsor/CRO is willing to act as Quorum’s primary study contact in order to assist investigators;
  • The study plan will include provisions for training new investigators as to their obligations, including safety reporting and communications with the IRB.

If you are interested in learning more about the phase IV pricing or you are wondering if your study would qualify, please contact us at customerrelations@quorumreview.com.